Polyglutamine disease and neuronal cell death.
作者信息
Paulson H L, Bonini N M, Roth K A
机构信息
Department of Neurology, University of Iowa College of Medicine, Iowa City, IA 52252, USA.
出版信息
Proc Natl Acad Sci U S A. 2000 Nov 21;97(24):12957-8. doi: 10.1073/pnas.210395797.
Abstract
摘要
相似文献
1
Polyglutamine disease and neuronal cell death.多聚谷氨酰胺疾病与神经元细胞死亡
Proc Natl Acad Sci U S A. 2000 Nov 21;97(24):12957-8. doi: 10.1073/pnas.210395797.
2
[Research progress in roles of microRNA in polyglutamine diseases].[微小RNA在多聚谷氨酰胺疾病中作用的研究进展]
Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2010 Aug;27(4):406-9. doi: 10.3760/cma.j.issn.1003-9406.2010.04.010.
3
Trinucleotide repeats and neurodegenerative disease.三核苷酸重复序列与神经退行性疾病。
Brain. 2004 Nov;127(Pt 11):2385-405. doi: 10.1093/brain/awh278. Epub 2004 Aug 25.
4
Identification of ter94, Drosophila VCP, as a modulator of polyglutamine-induced neurodegeneration.鉴定ter94（果蝇VCP）作为多聚谷氨酰胺诱导神经变性的调节因子。
Cell Death Differ. 2002 Mar;9(3):264-73. doi: 10.1038/sj.cdd.4400955.
5
[Polyglutamine diseases: a pathologic view].[聚谷氨酰胺疾病：病理视角]
Rinsho Shinkeigaku. 2003 Nov;43(11):903-5.
6
Polyglutamine diseases and molecular chaperones.多聚谷氨酰胺疾病与分子伴侣
IUBMB Life. 2003 Jun;55(6):337-45. doi: 10.1080/1521654032000114339.
7
Involvement of lysosomes in the pathogenesis of CAG repeat diseases.
Ann Neurol. 2002 Oct;52(4):498-503. doi: 10.1002/ana.10328.
8
[Advances in understanding of clinical presentations and molecular mechanisms of triplet repeat diseases].[三联体重复疾病临床表现及分子机制的认识进展]
Nihon Rinsho. 1999 Apr;57(4):778-86.
9
Therapeutic opportunities in polyglutamine disease.聚谷氨酰胺疾病的治疗机遇
Nat Med. 2001 Apr;7(4):419-23. doi: 10.1038/86486.
10
[MicroRNAs and polyglutamine diseases].[微小RNA与多聚谷氨酰胺疾病]
Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2013 Dec;30(6):683-6. doi: 10.3760/cma.j.issn.1003-9406.2013.06.011.
引用本文的文献
1
Evaluating Glial Fibrillary Acidic Protein and Neurofilament Light as Potential Biomarkers for Spinocerebellar Ataxia 7.评估胶质纤维酸性蛋白和神经丝轻链作为脊髓小脑共济失调7型潜在生物标志物的作用。
Int J Mol Sci. 2025 May 24;26(11):5070. doi: 10.3390/ijms26115070.
2
Identifying Molecular Properties of Ataxin-2 Inhibitors for Spinocerebellar Ataxia Type 2 Utilizing High-Throughput Screening and Machine Learning.利用高通量筛选和机器学习确定2型脊髓小脑共济失调中ataxin-2抑制剂的分子特性
Biology (Basel). 2025 May 8;14(5):522. doi: 10.3390/biology14050522.
3
Structural-functional analyses of the huntingtin/HAP40 complex in and humans.亨廷顿蛋白/HAP40复合物在小鼠和人类中的结构功能分析。
J Biomol Struct Dyn. 2025 Mar 17:1-16. doi: 10.1080/07391102.2025.2474683.
4
Neuroprotective Potential of Eugenol in Polyglutamine-Mediated Neurodegenerative Disease Using Transgenic Model.丁香酚在多聚谷氨酰胺介导的神经退行性疾病转基因模型中的神经保护潜力
Dose Response. 2024 Oct 13;22(4):15593258241291652. doi: 10.1177/15593258241291652. eCollection 2024 Oct-Dec.
5
Cathepsin B promotes Aβ proteotoxicity by modulating aging regulating mechanisms.组织蛋白酶 B 通过调节衰老调节机制促进 Aβ 蛋白毒性。
Nat Commun. 2024 Oct 3;15(1):8564. doi: 10.1038/s41467-024-52540-x.
6
Polyglutamine (PolyQ) Diseases: Navigating the Landscape of Neurodegeneration.多聚谷氨酰胺（PolyQ）疾病：探索神经退行性变的全景。
ACS Chem Neurosci. 2024 Aug 7;15(15):2665-2694. doi: 10.1021/acschemneuro.4c00184. Epub 2024 Jul 12.
7
Neuroprotective effects of flavonoids: endoplasmic reticulum as the target.类黄酮的神经保护作用：以内质网为靶点。
Front Neurosci. 2024 Jun 18;18:1348151. doi: 10.3389/fnins.2024.1348151. eCollection 2024.
8
Base editing strategies to convert CAG to CAA diminish the disease-causing mutation in Huntington's disease.将CAG转换为CAA的碱基编辑策略可减少亨廷顿舞蹈病中的致病突变。
Elife. 2024 Jun 13;12:RP89782. doi: 10.7554/eLife.89782.
9
The deubiquitinase function of ataxin-3 and its role in the pathogenesis of Machado-Joseph disease and other diseases.ataxin-3 的去泛素化酶功能及其在 Machado-Joseph 病和其他疾病发病机制中的作用。
Biochem J. 2024 Mar 20;481(6):461-480. doi: 10.1042/BCJ20240017.
10
Modification of Huntington's disease by short tandem repeats.短串联重复序列对亨廷顿舞蹈症的修饰作用
Brain Commun. 2024 Jan 23;6(2):fcae016. doi: 10.1093/braincomms/fcae016. eCollection 2024.
本文引用的文献
1
Mechanisms of programmed cell death in the developing brain.发育中大脑的程序性细胞死亡机制。
Trends Neurosci. 2000 Jul;23(7):291-7. doi: 10.1016/s0166-2236(00)01581-2.
2
Glutamine repeats and neurodegeneration.谷氨酰胺重复序列与神经退行性变。
Annu Rev Neurosci. 2000;23:217-47. doi: 10.1146/annurev.neuro.23.1.217.
3
Polyglutamine aggregates alter protein folding homeostasis in Caenorhabditis elegans.多聚谷氨酰胺聚集体改变秀丽隐杆线虫中的蛋白质折叠稳态。
Proc Natl Acad Sci U S A. 2000 May 23;97(11):5750-5. doi: 10.1073/pnas.100107297.
4
The Bcl-2 protein family.Bcl-2蛋白家族。
Exp Cell Res. 2000 Apr 10;256(1):50-7. doi: 10.1006/excr.2000.4839.
5
Genetic suppression of polyglutamine toxicity in Drosophila.果蝇中多聚谷氨酰胺毒性的基因抑制
Science. 2000 Mar 10;287(5459):1837-40. doi: 10.1126/science.287.5459.1837.
6
Aggregation of huntingtin in yeast varies with the length of the polyglutamine expansion and the expression of chaperone proteins.亨廷顿蛋白在酵母中的聚集情况会因聚谷氨酰胺扩展的长度以及伴侣蛋白的表达而有所不同。
Proc Natl Acad Sci U S A. 2000 Feb 15;97(4):1589-94. doi: 10.1073/pnas.97.4.1589.
7
Suppression of polyglutamine-mediated neurodegeneration in Drosophila by the molecular chaperone HSP70.分子伴侣HSP70对果蝇中多聚谷氨酰胺介导的神经变性的抑制作用。
Nat Genet. 1999 Dec;23(4):425-8. doi: 10.1038/70532.
8
Analysis of the role of heat shock protein (Hsp) molecular chaperones in polyglutamine disease.热休克蛋白（Hsp）分子伴侣在多聚谷氨酰胺疾病中的作用分析。
J Neurosci. 1999 Dec 1;19(23):10338-47. doi: 10.1523/JNEUROSCI.19-23-10338.1999.
9
Insoluble detergent-resistant aggregates form between pathological and nonpathological lengths of polyglutamine in mammalian cells.在哺乳动物细胞中，病理性和非病理性长度的聚谷氨酰胺之间会形成不溶性抗去污剂聚集体。
Proc Natl Acad Sci U S A. 1999 Sep 28;96(20):11404-9. doi: 10.1073/pnas.96.20.11404.
10
Inhibition of caspase-1 slows disease progression in a mouse model of Huntington's disease.在亨廷顿舞蹈病小鼠模型中，半胱天冬酶-1的抑制作用减缓了疾病进展。
Nature. 1999 May 20;399(6733):263-7. doi: 10.1038/20446.
Zotero 插件